Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010633 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT01010633 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 406 participants.
The verdict
NCT01010633, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Interventions
- DRUG Loteprednol Etabonate
- DRUG Vehicle of Loteprednol Etabonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010633
The ClinicalTrials.gov registry entry for NCT01010633 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol Etabonate is the first listed.
NCT01010633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01010633 about?
NCT01010633 is a clinical study titled "Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery". This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
What is the current status of trial NCT01010633?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2009-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01010633?
The interventions under investigation include: Loteprednol Etabonate (DRUG), Vehicle of Loteprednol Etabonate (DRUG).
Who is sponsoring clinical trial NCT01010633?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.